Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma

Multiple myeloma (MM) is a hematological malignancy characterized by high risk for thrombotic episodes, mainly venous thromboembolism (VTE). This accentuated cancer treatments such as immunomodulatory drugs (IMiDs). Cancer-associated thrombosis one of the leading causes mortality and morbidity, prevention is, therefore, paramount significance. To this day, it unclear which type thromboprophylaxis most effective. partly due to multifactorial etiology behind since compound patient-, disease- treatment-associated factors characterizing each patient with MM unique. Additionally, established scores are not reliable in patients MM. The scope review summarize contributing increased MM, well regimes available.